Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKinsey
Mallinckrodt
Harvard Business School
Dow

Last Updated: May 26, 2022

CRIXIVAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Crixivan patents expire, and what generic alternatives are available?

Crixivan is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indinavir sulfate profile page.

Drug patent expirations by year for CRIXIVAN
Drug Prices for CRIXIVAN

See drug prices for CRIXIVAN

Recent Clinical Trials for CRIXIVAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oncology Institute of Southern SwitzerlandPhase 2
Emory UniversityPhase 4
National Institutes of Health Clinical Center (CC)Phase 1

See all CRIXIVAN clinical trials

US Patents and Regulatory Information for CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CRIXIVAN

International Patents for CRIXIVAN

See the table below for patents covering CRIXIVAN around the world.

Country Patent Number Title Estimated Expiration
Cyprus 2326 HIV protease inhibitors in pharmaceutical combinant for the treatment of AIDS. See Plans and Pricing
Canada 2120192 See Plans and Pricing
Cyprus 2090 Hiv protease inhibitors useful for the treatment of aids See Plans and Pricing
Australia 5921394 See Plans and Pricing
Mexico 9705916 TERAPIA DE COMBINACION PARA INFECCION POR VIH USANDO EL INHIBIDOR DE PROTEASA DE VIH INDINAVIR Y EL INHIBIDOR DE TRANSCRIPTASA INVERSA 3TC, OPCIONALMENTE JUNTO CON AZT, DDI, O DDC. (COMBINATION THERAPY FOR HIV INFECTION USING THE HIV PROTEASE INHIBITOR INDINAVIR ADN THE REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, DDI OR DDC.) See Plans and Pricing
Finland 973184 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Mallinckrodt
Baxter
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.